Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26
Rhea-AI Summary
Nu Skin Enterprises (NYSE:NUS) reported 2Q26 revenue of $320.1M, adjusted net income of $10.0M and adjusted EPS of $0.20, matching Stonegate Capital Partners’ EPS estimate but below its revenue estimate of $345.2M. GAAP EPS was ($5.14), mainly due to a $78.9M non-cash goodwill impairment and a $167.5M deferred-tax valuation allowance, both excluded from adjusted results.
Core Nu Skin gross margin rose 20 bps year over year to 77.7%, while consolidated gross margin fell 60 bps to 68.2% and adjusted operating margin declined 190 bps to 6.1%. Nu Skin and Rhyz revenue fell 15.5% and 25.0% year over year, respectively. Management reduced FY26 revenue guidance to $1.28B–$1.35B from $1.35B–$1.50B and adjusted EPS guidance to $0.70–$0.90 from $0.80–$1.20, and shifted the India market timing to 1H27. The Prysm iO platform remains the key growth initiative, with over 39,000 devices placed, 2.5M scans completed, and a year-end target of 50,000–60,000 devices, alongside early signs of sales-leader stabilization.
Positive
- Adj. EPS $0.20 met Stonegate estimate despite revenue shortfall
- Core Nu Skin gross margin improved 20 bps y/y to 77.7%
- Prysm iO rollout exceeds 39,000 devices and 2.5M scans with 50,000–60,000 targeted by year-end
- Mainland China sales leaders increased 2% y/y, showing localized strength
- Sales leaders down 9% y/y vs 13% in 1Q and essentially flat q/q, indicating stabilization
Negative
- Revenue $320.1M missed Stonegate’s $345.2M estimate
- Nu Skin and Rhyz revenue declined 15.5% and 25.0% y/y, respectively
- Consolidated gross margin fell 60 bps to 68.2%; adjusted operating margin down 190 bps to 6.1%
- GAAP EPS ($5.14) driven by $78.9M goodwill impairment and $167.5M deferred-tax valuation allowance
- FY26 revenue guidance cut to $1.28B–$1.35B and adjusted EPS to $0.70–$0.90
- India market entry shifted from year-end 2026 to 1H27; recruiting remains below sustainable-growth levels
Details
News Market Reaction – NUS
On Aug 12, the first trading day after this news, NUS closed 0.51% below the previous close. Our momentum scanner recorded 11 alerts for this stock that day. Relative volume reached 2.4x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 12 session.
Key Figures
- Revenue
- $320.1M
- 2Q26; versus $345.2M estimate
- Adjusted net income
- $10.0M
- 2Q26; versus $10.3M estimate
- Adjusted EPS
- $0.20
- 2Q26; matched estimate
- GAAP EPS
- $(5.14)
- 2Q26; primarily reflected non-cash charges
- Goodwill impairment
- $78.9M
- 2Q26 non-cash charge
- Deferred-tax valuation allowance
- $167.5M
- 2Q26; excluded from adjusted results
- Core Nu Skin gross margin
- 77.7%
- 2Q26; improved 20 bps year over year
- FY26 guidance
- $1.28B-$1.35B revenue; $0.70-$0.90 adjusted EPS
- Reduced from $1.35B-$1.50B revenue and $0.80-$1.20 adjusted EPS
Historical Context
-
Company scheduled second-quarter results release and investor conference call.
-
Nourish the Children initiative reported 900 million meals provided since 2002.
-
Quarterly revenue declined 12% year over year amid customer and affiliate declines.
-
Board declared a quarterly cash dividend of $0.06 per share.
-
Company scheduled first-quarter results release and investor conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
goodwill impairment financial
deferred-tax valuation allowance financial
gross margin financial
adjusted operating margin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dallas, Texas--(Newsfile Corp. - August 11, 2026) - NU Skin Enterprises Inc. (NYSE: NUS): Stonegate Capital Partners updates their coverage on NU Skin Enterprises Inc. (NYSE: NUS). NUS reported revenue, adj NI, and adj EPS of
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Revenue was
$320.1M in 2Q26, while adj. EPS of$0.20 m atched our estimate despite a weaker top line, with Core Nu Skin gross margin improving 20 bps y/y to77.7% . Management lowered FY26 revenue guidance to$1.28B -$1.35B and adjusted EPS guidance to$0.70 -$0.90 , reinforcing a softer near-term setup but leaving margin improvement and cost optimization as important levers into 2027. - Prysm iO remains the central longer-term growth initiative, with more than 39,000 devices placed and 2.5M scans completed as NUS targets 50,000-60,000 devices by year-end. We increasingly view the platform as a sales-force productivity tool, with AI-enabled assessments, recommendations, and 90-day wellness plans expected to help leaders deepen customer engagement, improve conversion, and broaden monetization across beauty and wellness.
- Sales-force trends showed early signs of stabilization, with sales leaders down
9% y/y versus a13% decline in 1Q and essentially flat q/q, while Mainland China sales leaders increased2% y/y. Although recruiting remains below levels required for sustainable growth and India has shifted to 1H27, Prysm iO training, compensation changes, leadership development initiatives, and the East-West operating model provide several potential drivers for improved productivity and profitability next year.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309257
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
